It is also reasonable to assume that the individual patients suffering from the coexisting cardiovascular and metabolic diseases may respond differently to the complex pharmacological therapies that target RAS, VS, and insulin receptor signaling. This evidence concerns the gene INSR and Other metabolic disease.